From: The effect of Parkinson’s disease on total knee arthroplasty: a systematic review and meta-analysis
Journal | Year | Author | Study design | Level of evidence | Disease severity | Follow-up duration | Number (PD) | Number (control) | Age in years |
---|---|---|---|---|---|---|---|---|---|
Acta Orthop. Belg | 2013 | Craig | Retrospective case-controlled study | III | No information | 5 years | 32 | 33 | Mean 73 |
JBJS | 2014 | Jämsen | Registry-based case-controlled study | III | No information | PD: median 5.4 years Control: median 5.5 years | 560 | 1680 | PD: median 72 Control: median 73 |
J Arthroplasty | 2017 | Rodon | Retrospective case-controlled study | III | Charlson Comorbidity index PD: 3.72 ± 0.14 Control: 3.84 ± 0.12 | 5.3years | 71 | 132 | PD: 68.5 ± 1.13 Control: 69.7 ± 0.77 |
J Arthroplasty | 2018 | Wong | Retrospective cohort study | III | No information | 1 year | 35 | 41 | PD: 72.6 ± 7.3 Control: 71.8 ± 7.6 |
J Orthop Surg Res | 2019 | Xiao | Retrospective case series | IV | Hoehn and Yahr stage I: 2, II: 7, III: 5, IV: 4 | Median 38 months | 18 | 67.89 ± 6.62 | |
KSSTA | 2019 | Newman | Registry-based case-controlled study | III | Charlson Comorbidity index PD: 0: 59% (18,928), 1: 26% (8288), ≥ 2: 15% (4705) Control: 0.59% (56,707), 1: 26% (24,827), ≥ 2: 15% (14,062) | 31,921 | 95,596 | PD: 72 ± 8.1 Control: 72 ± 8.1 | |
Knee | 2019 | Kleiner | Registry-based case-controlled study | III | Charlson Comorbidity index PD: 0.56 ± 0.01 Control: 0.58 ± 0.00 | 7361 | 73,610 | PD: 72.0 ± 0.1 Control: 72.1 ± 0.03 | |
AOTS | 2020 | Veronica | Retrospective cohort study | IV | Modified Hoehn and Yahr stage 1.5 | 3.5 years | 26 | 71 (range 61–83) | |
JKS | 2020 | Marchand | Registry-based case-controlled study | III | Elixhauser Comorbidity index PD: 9 ± 4 Control: 9 ± 4 | 2 years | 18,082 | 54,244 | < 64: PD (2255), Control (6765) 65–69: PD (4740), Control (14,220) 70–74: PD (4483), Control (13,448) 75–79: PD (3867), Control (11,601) 80–84: PD (2008), Control (6024) < 85: PD (565), Control (4695) Unknown: PD (164), Control (491) |
J Arthroplasty | 2020 | Goh | Retrospective case-controlled study | III | Hoehn and Yahr stage I: 34, II: 12, III: 9, IV: 2 | 2 years | 57 | 57 | PD: 69.3 ± 7.7 Control: 70.1 ± 8.6 |
J Orthop Sci | 2020 | Ergin | Retrospective case-controlled study | III | Columbia stage in PD I: 2, II: 7, III: 4 | PD: 64.5 ± 44.7 months Control: 51.8 ± 13.6 months | 13 | 13 | PD: 75.6 ± 8.13 Control: 71.4 ± 9.07 |
Int Orthop | 2021 | Baek | Retrospective case-controlled study | III | Koval’s grade PD: I (25), II (4) Control: I (51), II (7) | PD: mean 133.0 months Control: mean 133.1 months | 29 | 58 | PD: 71.0 ± 5.8 Control: 71.2 ± 5.6 |
BMC Musculoskeletal Disorders | 2022 | Y. Zong | Retrospective case-controlled study | III | Hoehn and Yahr stage 2.3 ± 0.9 | PD: 13.8 ± 7.2 months Control: 14.5 ± 8.3 months | 12 | 48 | PD: 65.4 ± 11.4 Control: 65.2 ± 10.9 |
J of AAOS | 2022 | Cheppalli | Registry-based case-controlled study | III | No information | 4 years | 3082 | 555,289 | PD: 71.44 ± 7.88 Control: 66.59 ± 9.50 |